Loading patent…
AssigneesTechnion Research & Development Foundation Limited, Yeda Research and Development Co. Ltd.
InventorsMoussa Youdim, Matityahu Fridkin, Hailin Zheng, Abraham Warshawsky, Rivka Warshawsky
Estimating the term…
Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, eg. a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, a inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding ageing, and prevention and/or treatment of skin ageing and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety, the neuroprotective function is imparted to the compound e.g. by a neuroprotective peptide, and a combined antiapoptotic and neuroprotective function by a propargyl group.
A compound comprising an iron chelator function and a residue selected from the group consisting of a residue that imparts a neuroprotective function to the compound, a residue that imparts combined antiapoptotic and neuroprotective function to the compound, or both.
61-78. (canceled)
(canceled)
A method for iron chelation therapy which comprises administering to an individual in need thereof an effective amount the compound 5-(4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline (herein identified as VK-28, Appendix IV) for treatment and/or prevention of a disease, disorder or condition associated with iron overload and oxidative stress, excluding the prevention and/or treatment of a neurodegenerative disease, condition or disorder.
A cosmetic composition for topical application for prevention and/or treatment of skin ageing and/or skin damage associated with ageing and/or exposure to sunlight and/or UV light comprising the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline (herein identified as VK-28, Appendix IV).
A method for preservation of organs intended for transplantation such as heart, lung or kidney which comprises treating said organ ex-vivo with the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline (herein identified as VK-28, Appendix IV).
(canceled)
(canceled)
A method for the treatment and/or prevention of a disease, disorder or condition associated with iron overload and oxidative stress, excluding the prevention and/or treatment of a neurodegenerative disease, condition or disorder, which comprises administering to an individual in need thereof an effective amount of the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline (herein identified as VK-28, Appendix IV).
Dependencies are inferred from the claim text.